ISIS Pharmaceuticals Inc $34.01

down -0.56


17/4/2014 08:10 PM  |  NASDAQ : ISIS  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get ISIS Trend Analysis - it has outperformed the S&P 500 by 57%

Partner Headlines

  1. Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx

    Benzinga
  2. EARLIER: Isis Announces Antisense Targeting of HBV Produces Dose-Dependent ...

    Benzinga
  3. BioMed Realty Trust Leases Space To Life Science Firms

    IBD
  4. US Stock Futures Edge Higher; All Eyes On Fed

    Benzinga
  5. US Stock Futures Tumble Ahead Of Economic Data

    Benzinga
  6. Earnings Scheduled For February 28, 2014

    Benzinga
  7. Mid-Afternoon Market Update: Groupon Shares Continue to Show Weakness Following ...

    Benzinga
  8. Mid-Day Market Update: Acacia Research Shares Decline On Downbeat Results; ...

    Benzinga
  9. US Stock Futures Rise Ahead Of Existing-Home Sales Data

    Benzinga
  10. Isis Pharmaceuticals Earns $2M Milestone Payment from GSK for Advancement ...

    Benzinga
  11. UPDATE: Piper Jaffray Assumes Coverage on ISIS Pharmaceuticals as Company's ...

    Benzinga
  12. Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-GSK3 Rx, Earns $3M ...

    Benzinga
  13. Isis Pharmaceuticals Announces Plan Investigate Higher Dose of ISIS-SMN ...

    Benzinga
  14. Isis Pharmaceuticals Announces Fifth Positive Phase 2 Data Set for ISIS-APOCIII ...

    Benzinga
  15. Isis Pharmaceuticals Announces Positive Phase 1 Results with ISIS-APO(a) ...

    Benzinga
  16. Isis Pharmaceuticals Announces $1.5M Milestone Payment from Biogen Related ...

    Benzinga
  17. UPDATE: J.P. Morgan Initiates Coverage on Isis Pharmaceuticals, Awaiting ...

    Benzinga
  18. Benzinga's Top Initiations

    Benzinga
  19. ISIS Pharm Advances Phase 2 Study of ISIS-SMN Rx in Infants, Says Earns ...

    Benzinga
  20. Pharmaceutical Industry Expected To Collect Billions From Obamacare

    Benzinga
  21. Market Wrap For Monday, September 23: Markets Unmoved Despite Kenyan Terror

    Benzinga
  22. Mid-Afternoon Market Update: Celldex Therapeutics Rallies as Pandora Drops

    Benzinga
  23. Mid-Day Market Update: Oil Futures Tumble For Third Day in a Row; BlackBerry ...

    Benzinga
  24. Isis Reports Positive Phase 2 Data on ISIS-APOCIII Rx in Patients with ...

    Benzinga
  25. Isis Reports Follow-Up Data from Phase 1 ISIS-SMN Rx SMA Study

    Benzinga
  26. Market Wrap for Monday, September 9: Nasdaq Bounces To 13 Year High

    Benzinga
  27. Mid-Afternoon Market Update: Markets Lead by the NASDAQ as Various Health ...

    Benzinga
  28. Mid-Day Market Update: Dow Rises Over 100 Points; Apple Shares Gain

    Benzinga
  29. Isis Pharma, Biogen Idec to Tackle Brain Disorders

    FoxBusiness
  30. Benzinga's Volume Movers

    Benzinga
  31. Mid-Morning Market Update: Markets Open Higher; Koch Industries To Acquire ...

    Benzinga
  32. Goldman Sachs Reiterates Neutral Rating, $26 PT on ISIS Pharmaceuticals ...

    Benzinga
  33. Benzinga's Top Pre-Market Gainers

    Benzinga
  34. US Stock Futures Up Ahead Of Consumer Credit Data

    Benzinga
  35. Benzinga's Top Initiations

    Benzinga
  36. Benzinga's Top Pre-Market Gainers

    Benzinga
  37. Isis Reports Positive Interim Phase 2 Data on ISIS-APOCIII Rx

    Benzinga
  38. These ETFs House The Next Biotech Takeover Targets

    Benzinga
  39. Barron's Recap: The Changing World Of MLPs

    Benzinga
  40. Isis Pharmaceuticals

    IBD
  41. Needham Says Buy the Dip in Isis Pharma, Didn't See Favorable Chance CRP ...

    Benzinga
  42. Isis Pharmaceuticals Reports Phase 2 Data from Isis-CRP Rx RA Study

    Benzinga
  43. $176,000 or $295,00 a Year: Bizarre World of Orphan Drugs

    YCharts
  44. Market Wrap for Wednesday, January 30: Stocks Fall as Economy Contracts ...

    Benzinga
  45. Mid-Day Market Update: BlackBerry 10 Release Sends Shares Lower, Isis Pharma ...

    Benzinga
  46. UPDATE: Jefferies Reiterates Underperform Rating, Raises PT on ISIS Pharmaceuticals

    Benzinga
  47. Isis Pharmaceuticals to Provide Update on FDA Approval of KYNAMRO, 09:3 ...

    Benzinga
  48. Isis Pharmaceuticals (ISIS) Chairman, CEO and President Stanley T Crooke ...

    GuruFocus
  49. UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on ...

    Benzinga
  50. Mid-Afternoon Market Update: Markets Fall Further, Isis Pharma Rallies

    Benzinga
Trading Center